NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free SERA Stock Alerts $9.26 -0.53 (-5.41%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$8.68▼$9.7250-Day Range$8.94▼$11.6952-Week Range$1.52▼$12.35Volume284,464 shsAverage Volume110,387 shsMarket Capitalization$300.30 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sera Prognostics alerts: Email Address Sera Prognostics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside70.3% Downside$2.75 Price TargetShort InterestHealthy1.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 19 Articles This WeekInsider TradingSelling Shares$1.09 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.94) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.21 out of 5 starsMedical Sector783rd out of 925 stocksMedical Laboratories Industry17th out of 19 stocks 1.3 Analyst's Opinion Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSera Prognostics has only been the subject of 1 research reports in the past 90 days.Read more about Sera Prognostics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.11% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 15.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SERA. Previous Next 2.9 News and Social Media Coverage News SentimentSera Prognostics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Sera Prognostics this week, compared to 1 article on an average week.Search Interest4 people have searched for SERA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows2 people have added Sera Prognostics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,091,514.00 in company stock.Percentage Held by Insiders15.80% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sera Prognostics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($0.94) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sera Prognostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Sera Prognostics Stock (NASDAQ:SERA)Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Read More SERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SERA Stock News HeadlinesMay 11, 2024 | insidertrades.comSera Prognostics, Inc. (NASDAQ:SERA) Insider John J. Boniface Sells 4,902 SharesMay 12, 2024 | uk.investing.comSera Prognostics CFO sells shares worth over $63,000May 12, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 12, 2024 | investing.comSera Prognostics CEO sells shares worth over $115kMay 10, 2024 | finance.yahoo.comSera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic MovesMay 10, 2024 | finance.yahoo.comSera Prognostics First Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2024 Earnings Call TranscriptMay 8, 2024 | investorplace.comSERA Stock Earnings: Sera Prognostics Beats EPS for Q1 2024May 12, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 8, 2024 | prnewswire.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTSMay 8, 2024 | markets.businessinsider.comSera Prognostics A is about to announce its earnings — here's what Wall Street expectsApril 29, 2024 | prnewswire.comSera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024April 19, 2024 | morningstar.comSera Prognostics Inc Class AApril 16, 2024 | finance.yahoo.comEarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and TechnologyMarch 29, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 77,136 Shares of Sera Prognostics Inc (SERA)March 27, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)March 27, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA)March 21, 2024 | finanznachrichten.deSera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial ResultsMarch 21, 2024 | finance.yahoo.comSera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comSERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023March 20, 2024 | benzinga.comSera Prognostics: Q4 Earnings InsightsMarch 20, 2024 | finance.yahoo.comSERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTSMarch 20, 2024 | finance.yahoo.comSera Prognostics Inc Reports Modest Revenue Growth Amid Operational StreamliningMarch 19, 2024 | benzinga.comSera Prognostics's Earnings OutlookMarch 19, 2024 | markets.businessinsider.comSera Prognostics A is about to announce its earnings — here's what to expectMarch 19, 2024 | finance.yahoo.comCompanies Like Sera Prognostics (NASDAQ:SERA) Are In A Position To Invest In GrowthMarch 4, 2024 | prnewswire.comSera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024See More Headlines Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/12/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:SERA CUSIPN/A CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$2.75 Low Stock Price Target$2.75 Potential Upside/Downside-70.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,240,000.00 Net Margins-11,843.79% Pretax Margin-16,395.15% Return on Equity-46.35% Return on Assets-36.31% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.51 Sales & Book Value Annual Sales$310,000.00 Price / Sales968.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book4.63Miscellaneous Outstanding Shares32,430,000Free Float27,303,000Market Cap$300.30 million OptionableOptionable Beta1.33 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Evguenia Lindgardt M.B.A. (Age 50)President, CEO & Director Comp: $37.5kDr. Gregory C. Critchfield M.D. (Age 71)M.S., Executive Director Comp: $790.74kDr. Steven W. GravesCo-Founder and Co-Chairman of The Scientific Advisory BoardDr. M. Sean Esplin M.D.Co-Founder and Co-Chairman of Scientific Advisory BoardMr. Austin AertsChief Financial Officer??Dr. John J. Boniface Ph.D. (Age 62)Chief Scientific Officer Comp: $386.69kMr. Robert G. Harrison (Age 58)Chief Information Officer Comp: $384.18kMr. Benjamin G. Jackson J.D. (Age 45)General Counsel Comp: $410.75kDr. Paul Kearney Ph.D. (Age 56)Chief Data Officer More ExecutivesKey CompetitorsBiodesixNASDAQ:BDSXPersonalisNASDAQ:PSNLCelcuityNASDAQ:CELCCareDxNASDAQ:CDNALucid DiagnosticsNASDAQ:LUCDView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 13,339 shares on 5/10/2024Ownership: 2.763%Zhenya LindgardtSold 11,992 sharesTotal: $115,003.28 ($9.59/share)Austin AertsSold 6,592 sharesTotal: $63,217.28 ($9.59/share)John J BonifaceSold 4,902 sharesTotal: $47,010.18 ($9.59/share)Marquette Asset Management LLCSold 19,758 shares on 5/7/2024Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions SERA Stock Analysis - Frequently Asked Questions Should I buy or sell Sera Prognostics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SERA shares. View SERA analyst ratings or view top-rated stocks. What is Sera Prognostics' stock price target for 2024? 2 brokerages have issued twelve-month target prices for Sera Prognostics' stock. Their SERA share price targets range from $2.75 to $2.75. On average, they predict the company's share price to reach $2.75 in the next twelve months. This suggests that the stock has a possible downside of 70.3%. View analysts price targets for SERA or view top-rated stocks among Wall Street analysts. How have SERA shares performed in 2024? Sera Prognostics' stock was trading at $5.98 at the beginning of the year. Since then, SERA stock has increased by 54.8% and is now trading at $9.26. View the best growth stocks for 2024 here. When is Sera Prognostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our SERA earnings forecast. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) posted its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). The firm earned $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative trailing twelve-month return on equity of 46.35%. What ETF holds Sera Prognostics' stock? Invesco DWA SmallCap Momentum ETF holds 640,635 shares of SERA stock, representing 0.76% of its portfolio. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share. Who are Sera Prognostics' major shareholders? Sera Prognostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.76%), Commonwealth Equity Services LLC (0.18%), Sanders Morris Harris LLC (0.06%) and Marquette Asset Management LLC (0.04%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SERA) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.